Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Peringkat dalam Saham #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with NestlΓ© Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in PΓ©rigny, France.
Harga Saham
$0.94180721
Kapitalisasi Pasar
$22.26M
Perubahan (1 hari)
0.38%
Perubahan (1 tahun)
-14.35%
Negara
FR
Perdagangan Valbiotis SA (ALVAL)

Kategori

Rasio P/B untuk Valbiotis SA (ALVAL)
Rasio P/B per July 2026 TTM: 2.69
Menurut laporan keuangan dan harga saham terbaru dari Valbiotis SA, rasio P/B saat ini (TTM) adalah 2.69. Pada akhir 2023, rasio P/B perusahaan adalah 3.18.
Riwayat rasio P/B untuk Valbiotis SA dari 2015 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) 2.69 16.05%
2024 2.32 -27.16%
2023 3.18 16.23%
2022 2.74 -37.95%
2021 4.41 -30.21%
2020 6.32 392.65%
2019 1.28 -22.00%
2018 1.64 -0.78%
2017 1.66 -98.28%
2016 96.41 6,215.43%
2015 1.53 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.9942 159.78%
DK
6.251 132.17%
US
2.1715 -19.35%
US
4.065 50.98%
BE
7.3009 171.17%
NL